Results

Total Results: 2,065 records

Showing results for "years".

1. Celebrating 25 Years of AHRQ's Evidence-based Practice Center Program | Effective Health Care (EHC) Program
   effectivehealthcare.ahrq.gov/about/epc-25-years

2. Supporting Better Healthcare for 25 Years | Effective Health Care (EHC) Program
   effectivehealthcare.ahrq.gov/products/get-involved/25th-anniversary-brochure

3. AHRQ’s EPC Program: Supporting Better Healthcare for 25 Years (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/25th-anniversary-epc-brochure.pdf
   November 01, 2022 - AHRQ’s EPC Program: Supporting Better Healthcare for 25 Years AHRQ’s Evidence-based Practice Center … March 2022, AHRQ summarized primary care research gaps identified in evidence reviews from the last 3 years … 2022) Draft report coming spring 2023 AHRQ’s EPC Program: Supporting Better Healthcare for 25 Years

4. Cer-243-Prehospital-Airway-Management-Appendix-E-1 0 (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/cer-243-prehospital-airway-management-appendix-e-1_0.xlsx
   January 01, 2020 - February 2012 to March 2013 Adult Cardiac arrest Physician Paramedic Yes ETI Ground Included: age ≥18 years … Excluded: patients with penetrating STBI, those retrieved from other hospitals, and those below 18 years … : 23.5% 5-9 years: 26.3% 10-14 years: 29.4% ≥ 15 years: 16.8% NR NR High Cudnik, 2010 2010 0 0 0 ETI … : 959 (1.7) 6-10 years: 183 (0.3) 11-17 years: 606 (1.1) 18-30 years: 3666 (6.4) 31-50 years: 9192 (16.1 … ) 51-70 years: 21,518 (37.6) >70 years: 19,529 (34.1) Unknown: 1556 (2.7) Race: White: 69.5% Black:

5. Executive Summary_Systematic Review: Association of Digestible Carbohydrate Intake With Cardiovascular Disease, Type 2 Diabetes, Obesity, and Body Composition (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/effect-dietary-digestible-executive-summary.pdf
   March 01, 2025 - • No eligible studies evaluated children aged less than 18 years. … • No eligible studies evaluated children aged less than 18 years. … The median followup was 10.7 years, ranging from 1 to 32 years. … The median followup was 10.7 years, ranging from 1–32 years. … The median followup was 10.0 years, ranging from 16 weeks to 20 years.

6. Kidney-Stones-Draft-Appendi-C (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-stones-draft-appendi-c.xlsx
   January 01, 2024 - 650 mg BID Chlorthalidone 25 mg QD Chlorthalidone 50 mg QD Placebo 3 years 3 years Advice to increase … 2 years and at least 50% of the stone composition was calcium oxalate Aged 18 years or older with a … least two stones within previous 5 years and at least one stone within previous 2 years and at least … None 3 years per study protocol; actual followup varied from 1.7 to 2.7 years across groups Monitored … None 2 years Adherence to lemon juice: 79% at 6 months, 68% at 1 year, 48% at two years.

7. App-E-Surv-Report-3-Nonopioid-Pharmacol-Chronic-Pain (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-3-nonopioid-pharmacol-chronic-pain.xlsx
   May 29, 2025 - 2021 Pakistan Placebo-controlled Fair NPP (DPN) Age, mean: 45 Female: 0% Race: NR Pain duration: 2.6 years … Korea Head-to-head Fair NPP (DPN and PHN) Age, mean: 63 Female: 62% Race: NR Pain duration: 3.66 years … Zhang, 2021 China Fair Fibromyalgia Age, mean: 44 Female: 86% Race: Asian: 100% Pain duration: 5.8 years … Good Knee OA Age, mean: 65 Female: 42% Race: European: 89% Mãori: 10% Other: 8% Pain duration: 8 years … Khan Panezai, 2021 Pakistan Fair Knee OA Age, mean: 49 Female: 70% Race: NR Pain duration: 1.6 years

8. CER 218 Evidence Summary: Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-218-osteoporosis-fracture-prevention-evidence-summary.pdf
   April 01, 2019 - • Continuing bisphosphonates after 3–5 years versus discontinuation reduces some measures of vertebral … Mean participant age was 72 years, with all but two studies reporting mean age <80 years. … for 2 years, and intermediately increased in women assigned denosumab for 2 years, placebo for 1 year … Safety assessment of raloxifene over eight years in a clinical trial setting. … Ten years’ experience with alendronate for osteoporosis in postmenopausal women.

9. Please help find something to ease my mothers pain with restless leg syndrome? It has bothered her for over 30 years and now is almost unbearable at 78 years old. It has really diminished her joy in life. | Effective Health Care (EHC) Program
   effectivehealthcare.ahrq.gov/get-involved/nominated-topics/please-help-find-something-to-ease-my-mothers-pain-with-restless-leg-syndrome-it-has-bothered-her-for-over-30-years-and-now-is-almost-unbearable-at-78-years-old-it-has-really-diminished-her-joy-in-life

10. Therapies for Clinically Localized Prostate Cancer: Evidence Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/prostate-cancer-therapies-summary.pdf
    September 01, 2020 - Association (AUA) reviews.3-5 We included controlled studies of CLPC (stages T1–T3a) treatments ≥5 years … WW probably results in small to large increases in metastases through 15–20 years. … and late genitourinary toxicity over 3 years. … After 10 years, overall and prostate-cancer mortality were similar across all three treatments though … For most men with CLPC including those with life expectancies of 15–20 years, evidence indicates that

11. Intermittent Inhalded Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-194-evidence-summary-corticosteroids-asthma.pdf
    October 01, 2017 - of intermittent inhaled corticosteroid (ICS) therapy in different populations: – Patients 0 to 4 years … Key Messages • In children less than 5 years old with recurrent wheezing, intermittent use of inhaled … • In patients 12 years and older with uncontrolled, persistent asthma, adding long-acting muscarinic … e Effective Health Care Program Archived: This report is greater than 3 years old. … Patients 0 to 4 years old with recurrant wheezing Patients 25 years old with persistent asthma

12. Future Research Needs for Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers, Long-Term Effectiveness in All Ages, and Variability in Prevalence, Diagnosis, and Treatment (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/adhd-future_research.pdf
    May 01, 2012 - , and two issues for those ages 6 years and older. … Duration of the study would be several years at minimum. … 2 issues from older age group (6 years and older). … Research Needs for Those Less Than 6 Years of Age For children less than 6 years of age with disruptive … Research Needs for Those 6 Years of Age or Older For people ages 6 years or older with ADHD, what are

13. Disposition of Comments for CER 170 Cultural Competence Health Disparities (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/cultural-competence_disposition-comments.pdf
    January 01, 2020 - Archived: This report is greater than 3 years old. … for research purposes, but should not be considered current.Archived: This report is greater than 3 years … for research purposes, but should not be considered current.Archived: This report is greater than 3 years … for research purposes, but should not be considered current.Archived: This report is greater than 3 years … for research purposes, but should not be considered current.Archived: This report is greater than 3 years

14. MEDLINE Searches (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_appendixes.pdf
    March 01, 2009 - to 3.2 years. … Age 35 to 70 years; median age 51 years; 14% using estrogen. … Mean age 58 years. Multi-center with US sites. 60 mg/day; 2 years. … Mean age 60 years. France. 60 or 150 mg/day; 2 years. … Mean age 55.9 years (range 50- 64 years). United Kingdom. Dose varied; 2.6 years.

15. App-E-Surv-Report-1-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
    May 29, 2025 - 2021 Pakistan Placebo-controlled Fair NPP (DPN) Age, mean: 45 Female: 0% Race: NR Pain duration: 2.6 years … Korea Head-to-head Fair NPP (DPN and PHN) Age, mean: 63 Female: 62% Race: NR Pain duration: 3.66 years … Zhang, 2021 China Fair Fibromyalgia Age, mean: 44 Female: 86% Race: Asian: 100% Pain duration: 5.8 years … Good Knee OA Age, mean: 65 Female: 42% Race: European: 89% Mãori: 10% Other: 8% Pain duration: 8 years

16. Pediatric Quality Measures Program 3.0: An Evidence Map of Measures for Vision, Hearing, and Developmental Screening and Followup (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/pqmp-protocol.pdf
    April 01, 2014 - (at 5, 6, 8 and 10 years), and adolescence (at 12 and 15 years). … ), middle childhood (at 7 and 9 years), and adolescence (once during each age range of 11-14 years, … 15-17 years, and 18-21 years). … ) Middle Childhood (5 years to 10 years) Adolescence (11 years to 21 years) Vision Screening … of 11-14 years, 15-17 years, 18-21 years) Screen with audiometry including 6,000 and 8,000 Hz high

17. Attention Deficit Hyperactivity Disorder: Executive Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/adhd_executive.pdf
    October 01, 2011 - Three years after initiation, the four intervention groups showed comparable outcomes. … Relative benefits of the school­based intervention diminished over 2 years. … Age The age group ≈5­10 years appears to experience the highest prevalence. … Beyond 2 years, benefit appears to be highly variable. … Stimulant treatment over five years: adherence, effectiveness, and adverse effects.

18. Protocol for Quantitative Assessment of Benefit and Harm analysis of Aspirin for primary prevention (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-balancing-harms-benefits_research.pdf
    February 01, 2014 - 10 years. … person-years for women. … for men and 0.2 per 1,000 person-years for women), and for death (7.9 per 1,000 person-years for men … aged 75-84 years (example 2). … Input parameter: Time Person-years of exposure Estimated for 10 years Assumptions: baseline

19. Research Protocol: Safety of Vaccines Used for Routine Immunization in the United States (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/safety-vaccines-protocol.pdf
    January 30, 2020 - (Adacel); routine 10 years and older (Boostrix); routine; both can be used as young as 7 years … DTaP-IPV/Hib Pentacel 6 weeks through 4 years DTaP-IPV Kinrix Quadracel 4 years through 6 years … MMR-V ProQuad 12 months through 12 years DTaP-IPV-Hib-HepB Vaxelis* 6 weeks through 4 years Note … (HPV; also called HPV9) Gardasil 9 9 through 45 years; through 26 years Influenza, inactivated … (Adacel) 10 years and older (Boostrix) Tdap or Td; both can be used as young as 7 years for catch

20. Masks-Appendix-Table-B-2-Surveillance-Report (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/Masks-appendix-table-b-2-surveillance-report.xlsx
    March 01, 2020 - Link/URL Study Design Study Dates Geographic Setting Setting Inclusion Criteria Sample Size Age (mean, years … 355 (124 households with index cases) Not reported for family contacts Among index cases, 45% <18 years … , 74% 18–59 years, 26% ≥60 years Not reported for family contacts Among index cases, 51% SARS-CoV-2 … close community contacts of laboratory-confirmed SARS-1 cases 212 (contacts of 45 cases) Median age 33 years … secondary infection of household member 131 cases and 2,139 controls Mean not reported; 47% age 18–30 years